These data suggests that PVT1 can potentiate MYC in human cancers. CRISPR-cas9 mediated deletion of PVT1 in HCT116 impaired tumor formation in xenografts, and significantly reduced MYC levels. Additionally, we have identified the putative functional domain of PVT1 which confers its oncogenic potential. We have recently discovered that the exon 2 of PVT1 can undergo 'backsplicing' and form circular RNA of 410 bases (CircPVT1). This CircPVT1 is more abundant in MYC-driven cancer cell lines. Though PVT1 is known as a long non-coding RNA, we found that CircPVT1 can form an open reading frame (ORF) of 104 amino acids, which we have annotated as PVT1 encoded protein upon circularization (PEPc). While CRISPR-Cas9 mediated deletion of PVT1 exon 2 results into decreased MYC levels and reduced transformation potential in MYC-driven cancer cells, PEPc can independently augment MYC when added exogenously to LNCaP cells, and increase their transformation potential.
CONCLUSIONS: These results suggest that PEPc may play a key role in boosting MYC levels in metastatic prostate cancers. We propose that the dependence of high levels of MYC on PVT1 provides a much-needed therapeutic window against MYC protein, known to be refractory to small molecule inhibition. Although ADT initially achieves significant clinical response, PCa eventually relapses and progresses into castration-resistant prostate cancer (CRPC), a more aggressive form of PCa characterized by the resistance to ADT manipulation. Recent studies have demonstrated that remaining AR remains critical to the development of CRPC. Therefore, better dissecting the mechanism(s) underlying the targeting AR in CRPC would hold promise for overcoming the challenge of CRPC treatment.
METHODS: LNCaP, DU145 and C4-2 were employed in this study. A series of cell and tumor, biochemical, molecular biologic assays such as UV Cross-Linking and Immunoprecipitation (CLIP) assay,RNA Immunoprecipitation, TUNEL assay,RNA-pull down assay, Proliferation assay, Luciferase assay were carried out.
RESULTS: We found that GAS5, a long non-coding RNA (lncRNA), could interact and suppress AR transactivation in castration resistant PCa C4-2 cells. Targeting lncRNA-GAS5 by siRNA enhanced the expression of AR target gene PSA via alteration of AR recruitment to the PSA promoter. The consequences of suppression of AR transactivation led to suppress cell proliferation and enhance cell apoptosis in C4-2 cells in the castration resistant condition. In return, the suppressed AR could also modulate the lncRNA-GAS5 expression in a feedback regulation mechanism. the figure shows GAS5 was downregulated in clinical CRPC specimen compared to primary PCa samples. A gene expression microarray dataset (GSE22606) deposited in public database was analyzed, where n denotes the mumble of total samples and p stands for the adjusted R statistical p value.
CONCLUSIONS: These results revealed that LncRNA-GAS5 might play important roles to target the remaining AR signals in PCa at the castration resistant stage and targeting LncRNA-GAS5 to alter these remaining AR signals in CRPC.
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MP99-20 ALLYL ISOTHIOCYANATE UP-REGULATES MIR-30A-5P EXPRESSION THROUGH A ROS RESPONSIVE TRANSCRIPTION FACTOR, ACTIVATOR PROTEIN 1 (AP-1)
Hung-En Chen*, J-Fan Lin, Yi-Chia Lin, Te-Fu Tsai, Kuang-Yu Chou, Thomas I. S. Hwang, Taipei, Taiwan INTRODUCTION AND OBJECTIVES: Allyl isothiocyanate (AITC) is one of the most widely studied isothiocyanates that inhibits the survival of human prostate cancer (PCa) cells while not affecting normal prostate epithelial cells. microRNA 30a-5p (miR-30a-5p) was reported as a tumor suppressor and regulates epithelial to mesenchymal transition (EMT) in bone metastasis and castration-resistant PCa. In this study, we investigated whether AITC affects the expression of miR-30a-5p and the mechanism underlying this regulation.
METHODS: Human PCa cell lines (Rv1 and PC3) were used in this study. The expression level of miR-30a-5p in AITC-treated cells was detected using stem-loop RT and QPCR. The expression of a validated miR-30a-5p target Ets Related Gene (ERG) by QPCR and Western blot in cells treated with AITC or transfected with miR-30a-5p. The expression level of phosphor-c-jun was detected by immunofluorescent and Western blot. Reporter vector bearing antisense sequence of miR-30a-5p was served as inhibitor of AITC-induced miR-30a-5p.
RESULTS: The expression of miR-30a-5p was increased in AITC-treated cells. The expression of ERG was down-regulated in AITC-treated or miR-30a-5p transfected cells. The expression of ERG was attenuated in AITC-treated cells transfected with miR-30a-5p antisense inhibitor, suggesting AITC regulates ERG expression through miR-30a-5p. Furthermore, we found the AP-1 is a potential regulator of miR-30a-5p expression by analyzing 10 kb nucleotides sequence upstream of miR-30a-5. Accumulation of c-Jun was detected in AITCtreated cells, and treatment of ROS inhibitor or catalase inhibitor attenuated AITC-induced c-Jun activation, suggesting AITC activates c-Jun translocation was mediated by AITC-induced ROS. In addition, the up-regulated miR-30a-5p was also attenuated in AITC-treated cells pretreated with catalase-inhibitor further provide evidence that miR-30a-5p is an important effector of AITC.
CONCLUSIONS: Herein, we show for the first time that AITC regulates the expression of miR-30a-5p through ROS generation and AP-1 activation. These results could potentially contribute to a therapeutic application of AITC in prostate cancer patients.
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